Sana biotechnology announces increased focus on hypoimmune-related pipeline with the potential to deliver clinical proof of concept data from four programs in 2023 and 2024 with a 2024 operating burn under $200m

Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmune (hip)-modified cells to evade immune detection
SANA Ratings Summary
SANA Quant Ranking